Reaction Biology, 4HF Biotec offer new cell-based services October 19, 2020 -- Reaction Biology and 4HF Biotec announced that they are offering a new cell-based service that will give customers a comprehensive understanding of their candidates. The service will combine Reaction's ProLiFiler cell assay service with 4HF's Biomarker Analysis and Mode of Action (MoA) Finder tools
OneOncology launches OneR, precision oncology research network October 19, 2020 -- OneOncology has formed a subsidiary named OneOncology Research Network (OneR) as a national nonexclusive clinical trial site management organization to enhance research programs underway at participating community oncology practices.
Endo to acquire BioSpecifics October 19, 2020 -- Endo will acquire all shares of BioSpecifics Technologies for $88.50 per share, or an estimated total of $540 million. As part of the acquisition, BioSpecifics will receive a royalty stream from Endo's collagenase-based therapies, including Xiaflex and Qwo, which were developed by BioSpecifics.
CHMP recommends approval for Janssen's mAb in psoriatic arthritis October 16, 2020 -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval for the expanded use of guselkumab (Tremfya), a monoclonal antibody (mAb) from the Janssen Pharmaceutical Companies of Johnson & Johnson.